Inspire Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Inspire Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,161	Closed	-$232K	–	771
2026 Q1	$232K	Buy	+1,161	New	+$230K	0.02%	564
2022 Q2	–	Sell	-6,808	Closed	-$478K	–	144
2022 Q1	$478K	Buy	+6,808	New	+$494K	0.13%	31
2021 Q1	–	Sell	-8	Closed	–	–	444
2020 Q4	$0	Buy	+8	New	+$456	﹤0.01%	804

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inspire Advisors's LGND Position: Q2 2026 in Review

Inspire Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 1,161 shares — an estimated $232K sold.

Inspire Advisors first reported a position in LGND in Q4 2020 and held it in 3 quarters. The position peaked at $478K in Q1 2022. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Inspire Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Inspire Advisors sold 1,161 Ligand Pharmaceuticals shares in Q2 2026, an estimated $232K.
Inspire Advisors first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Inspire Advisors's Ligand Pharmaceuticals position peaked at $478K in Q1 2022.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Inspire Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.